Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma

A. R. Davies*, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck, N. Maisey, W. H. Allum, E. Smyth, J. A. Gossage, J. Lagergren, D. Cunningham, M. Green, M. Kelly, S. Ngan, A. Qureshi, A. Gaya, N. Griffin, A. Jacques, V. GohH. Deere, F. Chang, U. Mahadeva, B. Gill-Barman, S. George, J. Dunn, S. Zeki, J. Meenan, O. Hynes, G. Tham, C. Iezzi, D. Dellaportas, A. Cowie, W. Knight, N. Valeri, the Guy's and St Thomas' Oesophago-Gastric Research Group and PROGRESS Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)

Abstract

Background: The aim was to define the pathological response in lymph nodes following neoadjuvant chemotherapy for oesophageal adenocarcinoma and to quantify any associated survival benefit. Methods: Lymph nodes retrieved at oesophagectomy were examined retrospectively by two pathologists for evidence of a response to chemotherapy. Patients were classified as lymph node-negative (either negative nodes with no evidence of previous tumour involvement or negative with evidence of complete regression) or positive (allocated a lymph node regression score based on the proportion of fibrosis to residual tumour). Lymph node responders (score 1, complete response; 2, less than 10 per cent remaining tumour; 3, 10–50 per cent remaining tumour) and non-responders (score 4, more than 50 per cent viable tumour; 5, no response) were compared in survival analyses using Kaplan–Meier and Cox regression analysis. Results: Among 377 patients, 256 had neoadjuvant chemotherapy. Overall, 68 of 256 patients (26·6 per cent) had a lymph node response and 115 (44·9 per cent) did not. The remaining 73 patients (28·5 per cent) had negative lymph nodes with no evidence of regression. Some patients had a lymph node response in the absence of a response in the primary tumour (27 of 99, 27 per cent). Lymph node responders had a significant survival benefit (P < 0·001), even when stratified by patients with or without a response in the primary tumour. On multivariable analysis, lymph node responders had decreased overall (hazard ratio 0·53, 95 per cent c.i. 0·36 to 0·78) and disease-specific (HR 0·42, 0·27 to 0·66) mortality, and experienced reduced local and systemic recurrence. Conclusion: Lymph node regression is a strong prognostic factor and may be more important than response in the primary tumour.

Original languageEnglish
Pages (from-to)1639-1649
Number of pages11
JournalBritish Journal of Surgery
Volume105
Issue number12
Early online date22 Jul 2018
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Dive into the research topics of 'Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma'. Together they form a unique fingerprint.

Cite this